Tianjin Lisheng Pharmaceutical Co Ltd (002393) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a cash flow conversion efficiency ratio of 0.061x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥287.81 Million ≈ $42.12 Million USD) by net assets (CN¥4.69 Billion ≈ $686.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tianjin Lisheng Pharmaceutical Co Ltd (002393) defensive interval to measure how many days the company can operate on defensive assets alone.
Tianjin Lisheng Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Tianjin Lisheng Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tianjin Lisheng Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Lisheng Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
0.033x |
|
Jinzai Food Group Co Ltd
SHE:003000
|
0.137x |
|
Grupo KUO S.A.B. de C.V
MX:KUOB
|
0.005x |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
0.022x |
|
Zhuhai Port Co Ltd
SHE:000507
|
0.039x |
|
Misun Technology Co Ltd
SHE:301577
|
N/A |
|
Lao Feng Xiang Co Ltd B
SHG:900905
|
0.148x |
|
Ningxia Qinglong Pipes Industry Co Ltd
SHE:002457
|
0.044x |
Annual Cash Flow Conversion Efficiency for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Tianjin Lisheng Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.69 Billion ≈ $686.81 Million |
CN¥451.85 Million ≈ $66.12 Million |
0.096x | +423.55% |
| 2024-12-31 | CN¥4.80 Billion ≈ $702.39 Million |
CN¥88.26 Million ≈ $12.92 Million |
0.018x | -56.96% |
| 2023-12-31 | CN¥4.90 Billion ≈ $717.53 Million |
CN¥209.51 Million ≈ $30.66 Million |
0.043x | -43.92% |
| 2022-12-31 | CN¥4.35 Billion ≈ $636.45 Million |
CN¥331.38 Million ≈ $48.49 Million |
0.076x | +71.15% |
| 2021-12-31 | CN¥4.41 Billion ≈ $645.40 Million |
CN¥196.34 Million ≈ $28.73 Million |
0.045x | +150.77% |
| 2020-12-31 | CN¥4.30 Billion ≈ $629.53 Million |
CN¥76.37 Million ≈ $11.18 Million |
0.018x | -70.78% |
| 2019-12-31 | CN¥4.42 Billion ≈ $646.32 Million |
CN¥268.33 Million ≈ $39.26 Million |
0.061x | +19.96% |
| 2018-12-31 | CN¥3.21 Billion ≈ $470.07 Million |
CN¥162.69 Million ≈ $23.81 Million |
0.051x | -12.99% |
| 2017-12-31 | CN¥3.08 Billion ≈ $450.66 Million |
CN¥179.25 Million ≈ $26.23 Million |
0.058x | +1.09% |
| 2016-12-31 | CN¥3.02 Billion ≈ $441.21 Million |
CN¥173.60 Million ≈ $25.40 Million |
0.058x | -13.70% |
| 2015-12-31 | CN¥2.97 Billion ≈ $434.60 Million |
CN¥198.13 Million ≈ $28.99 Million |
0.067x | +168.73% |
| 2014-12-31 | CN¥2.91 Billion ≈ $425.81 Million |
CN¥72.24 Million ≈ $10.57 Million |
0.025x | -74.94% |
| 2013-12-31 | CN¥2.92 Billion ≈ $427.86 Million |
CN¥289.62 Million ≈ $42.38 Million |
0.099x | +10.09% |
| 2012-12-31 | CN¥2.79 Billion ≈ $407.77 Million |
CN¥250.72 Million ≈ $36.69 Million |
0.090x | +87.07% |
| 2011-12-31 | CN¥2.80 Billion ≈ $409.46 Million |
CN¥134.58 Million ≈ $19.69 Million |
0.048x | -31.68% |
| 2010-12-31 | CN¥2.65 Billion ≈ $387.79 Million |
CN¥186.55 Million ≈ $27.30 Million |
0.070x | -83.10% |
| 2009-12-31 | CN¥470.87 Million ≈ $68.90 Million |
CN¥196.14 Million ≈ $28.70 Million |
0.417x | +56.23% |
| 2008-12-31 | CN¥474.77 Million ≈ $69.47 Million |
CN¥126.59 Million ≈ $18.52 Million |
0.267x | -34.13% |
| 2007-12-31 | CN¥432.23 Million ≈ $63.25 Million |
CN¥174.94 Million ≈ $25.60 Million |
0.405x | -- |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more